Navigation Links
Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics
Date:6/24/2008

PALO ALTO, Calif., June 24 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that in conjunction with the commercial launch of Lexiscan(TM) by Astellas Pharma US, Inc., CV Therapeutics has earned a milestone payment of $10 million from TPG-Axon Capital, through an affiliated entity (TPG-Axon). CV Therapeutics will recognize the milestone as revenue earned in the second quarter of 2008.

The U.S. Food and Drug Administration (FDA) approved Lexiscan(TM) (regadenoson) injection, an A2A adenosine receptor agonist, for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress, on April 10, 2008.

On April 15, 2008, CV Therapeutics announced the completion of a non-dilutive financing transaction with TPG-Axon in which TPG-Axon agreed to pay up to $185 million in exchange for rights to 50 percent of its royalty on North American sales of Lexiscan(TM). CV Therapeutics received $175 million on closing of the transaction and has now earned an additional $10 million milestone associated with the commercial launch of the product, which Astellas announced today.

CV Therapeutics retains rights to the other 50 percent of royalty revenue from North American sales of the product, and also may receive a royalty on another Astellas product under the terms of the company's collaboration agreement with Astellas.

"The commercial launch of Lexiscan(TM) marks the culmination of a decade of work at CV Therapeutics where we discovered regadenoson and did the clinical, manufacturing and regulatory work needed to bring this important innovation to physicians and patients," said Louis G. Lange, CV Therapeutics chairman and chief e
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
2. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
3. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
4. ADVENTRX Appoints Vice President of Commercialization
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Accera, Inc. Names William T. Poncy Vice President of Commercial Development
7. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
8. Genencor Launches First Ever Commercial Enzyme Product for Cellulosic Ethanol
9. Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia
10. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
11. Product Development Timelines and Commercialization Strategy Are Focus of New Group at Premier Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
(Date:7/10/2014)... Terascala, the industry leader in ... a former vice president of product management for Flexera ... of marketing. Terascala’s software when combined with leading compute ... highest performance and most reliable solutions for processing big ... channel expansion and broaden its product portfolio. His leadership ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, ... announce the relaunch of his highly informative blog, now named ... “ What are Stem Cells ?” Dr. Harman’s purpose ... in the basics of stem cell therapy so that pet ... of treatment when considering regenerative medicine. , A veterinarian by ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded ... with a second treatment cup to help prevent and smooth ... is thinner on the edges for a softer contact with ... uneven surfaces on the face, neck and décolleté. Choose to ... areas such as the cheeks and neck, or opt for ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... , , , ... when revenues aren,t growing, many organizations are looking for ways to ... these things by better managing processes and the documents that go ... applications ( http://onbase.com/English/Products ). But here,s the roadblock: budgets ...
... , THE WOODLANDS, Texas, Sept. 9 Lexicon ... focused on discovering and developing breakthrough treatments for human disease, announced today ... and chief executive officer, will present at the Morgan Stanley Global Healthcare ... on Tuesday, September 15, 2009 at 1:35 p.m. Eastern Time. ...
... England, September 9 Clinical Therapeutics,(, http://www.clinicaltherapeutics.com/ ) ... the addition of Michael G. Spigarelli, MD, PhD,to ... As section editor for the Pediatric, Adolescent, ... Research section), Dr. Spigarelli brings a wealth of ...
Cached Biology Technology:Hyland Software Provides Grant Assistance to Kick-Start Technology Projects 2Hyland Software Provides Grant Assistance to Kick-Start Technology Projects 3Hyland Software Provides Grant Assistance to Kick-Start Technology Projects 4Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section 2
(Date:7/10/2014)...  Pomerantz LLP has filed a class action ... "Company")(NYSE-MKT: PVCT) and certain of its officers.  The ... Middle District of Tennessee , ... consisting of all persons or entities who purchased ... 2013 and May 22, 2014, both dates inclusive ...
(Date:7/10/2014)... SHELTON, Conn. , July 2, 2014 NXT-ID, Inc., ... market, reports that CEO Mr. Gino Pereira was ... radio show in Tampa Florida . Mr. ... radio host Cedric Harris and how the Wocket™ ... secure alternative.  Cedric Harris tells ...
(Date:7/10/2014)... 8, 2014 Fingerprint Cards, ... design win (DW). An Asian OEM has selected FPC1021 for ... start in August 2014.   FPC is proud ... has a planned date for start of mass production in ... of SEK 5M, for delivery in the first half of ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... an effective vaccine for hepatitis B and public health officials ... for the infectious liver disease, tens of thousands of people ... to a new study by researchers at Brown University, missed ... why infections persist. "This is a really simple thing ...
... - A comprehensive multi-disciplinary synthesis just published in ... investigation and policy development to address significant environmental, social ... climate change. "Effects of climate change on the ... synthesis of range change prediction in a warming world" ...
... Mass. Geoscientists at the University of Massachusetts Amherst ... first evidence that warm-cold climate oscillations well known in ... also appear as tropical rainfall variations in the Amazon ... expression of these cycles in the Southern Hemisphere. ...
Cached Biology News:Many high-risk Americans don't get hepatitis B vaccine 2Many high-risk Americans don't get hepatitis B vaccine 3Climate change invites alien invaders - Is Canada ready? 2Evidence of past Southern hemisphere rainfall cycles related to Antarctic temperatures 2
... be superior to transfection in some applications. ... PULSin you can study lethal proteins and ... proteins in cells. Likewise, delivery of blocking ... RNA interference experiments. ,With PULSin you ...
... an automated instrument with a thin silicon ... using light or fluorescence microscopy. Biaxial strain ... fibroblast cells can be simulated by mechanical ... Y axis of our strain chamber. Strain ...
... The versatile ST-195 allows real-time observations of ... This instrument has 64 different strain parameters ... incubator. The thin silicon strain chamber used ... microscopes and fluorescence microscopy. ST-195 can be ...
Immunogen GST fusion protein corresponding to full-length rat JNK3/ SAPK1b. Quality Assurance Routinely evaluated by immunoblot. Stability 2 years at -20°C from date of shipment GenBank A...
Biology Products: